DAVID HERRING: Open Payments
NPI 1336640788 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 46 payments from 18 companies in 2025. Trend: 2023 $97 · 2024 $589 · 2025 $872
Food & beverage: $872
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $122 |
| ABBVIE INC. | 5 | $114 |
| Novo Nordisk Inc | 6 | $106 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Astellas Pharma US Inc | 3 | $58 |
| Corcept Therapeutics | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Biogen, Inc. | 2 | $35 |
Products named: MOUNJARO, CAPLYTA, LEQEMBI, REXULTI, Veozah, QULIPTA, UBRELVY, Wegovy.
Industry payments across NC — which companies pay providers there.
